{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"Response criteria for subjects with WM is based upon the Consensus Panel Recommendations from the Third International Workshop on Waldenstrom Macroglobulinemia.\n\nOverall response rate (CR + PR + MR) measured at time of best response.","groups":[{"description":"Daily alternating thalidomide and lenalidomide plus rituximab (ThRiL) in patients with previously treated WM\n\nThalidomide: Thalidomide 50 mg (every ODD day of a 28 day cycle: Days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 \\& 27)\n\nLenalidomide: Lenalidomide (every EVEN day of a 28 day cycle: Days 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 \\& 28). Lenalidomide will be initiated at a starting dose of 5 mg.\n\nRituximab: Rituximab 375 mg/m2 IV on Days 1, 8, 15 and 22 (+/- 2 days) and then again on the same weekly x 4 schedule every 6th cycle thereafter (Cycle 7, 13, 19, etc).","id":"OG000","title":"All Patients"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Approximately 24 months","title":"Number of Patients Who Demonstrate a Response (Complete, Partial, Minor) to Treatment","type":"PRIMARY","unitOfMeasure":"participants"}